Sanofi: new data in multiple myeloma

(CercleFinance.com) - At the ASH meeting in San Diego Sanofi has announced the presentation of new data demonstrating the significant clinical benefit of Sarclisa-based quadruplets in patients with newly diagnosed multiple myeloma (MMND).


A new analysis of the IMROZ Phase III study combining Sarclisa with VRd demonstrated a sustained higher rate of MRD negativity in non-transplant-eligible MMND patients, compared with VRd alone.

According to detailed results from the GMMG-HD7 Phase III study, induction therapy with Sarclisa-RVd resulted in a significant and clinically meaningful benefit in terms of progression-free survival in transplant-eligible MMND patients.


Copyright (c) 2024 CercleFinance.com. All rights reserved.